Amicus Therapeutics (NASDAQ:FOLD) Downgraded by Guggenheim to “Hold”
Guggenheim lowered shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) from a strong-buy rating to a hold rating in a report released on Monday,Zacks.com reports. FOLD has been the topic of a number of other reports. TD Cowen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 [...]